Atara Biotherapeutics

Historical price data

Atara Biotherapeutics is a leader in allogeneic T-cell immunotherapy, focused on developing readily available, off-the-shelf cell therapies. Its landmark achievement is the European Commission approval of EBVALLO™ (tabelecleucel) for EBV+ PTLD, the first allogeneic T-cell therapy ever approved. The company's strategy centers on leveraging its proprietary EBV T-cell platform, which avoids gene editing, to build a pipeline targeting cancer and autoimmune diseases, while navigating the complex transition toward commercialization.

Proprietary Epstein-Barr Virus (EBV) T-cell platform that uses donor-derived, allogeneic T cells enriched for EBV specificity, eliminating the need for TCR or HLA gene editing and serving as a chassis for next-generation CAR T therapies.

Competes in allogeneic cell therapy with gene-editing focused firms like Allogene Therapeutics and CRISPR Therapeutics. Faces indirect competition from dominant autologous CAR-T players (Gilead/Kite, Bristol Myers Squibb). Holds a monopoly with EBVALLO for EBV+ PTLD in the EU, but future programs will face crowded, competitive markets.